ROC1 promotes the malignant progression of bladder cancer by regulating p-IκBα/NF-κB signaling

Qi Wu, Xiaqing Zhou, Peng Li, Mao Ding, Shengjie You, Zhaoyu Xu, Junjie Ye, Xuedong Chen, Mingyue Tan, Jun Wang, Wei Wang and Jianxin Qiu

Abstract

Background: Regulator of cullins 1 (ROC1) is an important catalytic subunit of cullin–RING E3 ligase. Nuclear factor-kappa B (NF-κB) signaling is closely related to tumor invasion and metastasis. Earlier, we reported that ROC1 was associated with a poor prognosis in patients with bladder cancer (BCa). However, it is unclear whether ROC1 is involved in the NF-κB signaling associated with malignant BCa progression.

Methods: The expression of ROC1 and p65 in bladder cancer and paracancerous tissues were detected by immunohistochemistry (IHC). Pearson correlation was used to assess correlation between ROC1 and p65 protein expressions. The wound-healing and transwell assays were used to monitor cell invasion and migration. The effect of ROC1 on the expression of key proteins in the NF-κB signaling was determined by immunofluorescence and western blot (WB). Cycloheximide (CHX), MG132 and immunoprecipitation assays were used to evaluate the effect of ROC1 on the ubiquitination of phosphorylated inhibitor of kappa B alpha (p-IκBα). A lung metastasis mouse model was generated to detect the role of ROC1 in tumor metastasis.

Results: We found that ROC1 was up-regulated in BCa tissues and cell lines, and high ROC1 levels were positively correlated with higher tumour grade, lymph node metastasis, distant metastasis and poor prognosis. Linear-regression analysis showed significant Pearson correlation between ROC1 and nuclear p65 expression in BCa tissue microarray (TMA) samples. Functional studies demonstrated that ROC1 promoted BCa cell invasion and migration. In vitro and in vivo experiments showed that ROC1 activated NF-κB signaling by enhancing the ubiquitination of p-IκBα, which caused p65 nuclear translocation and promoted the transcription of some metastasis-related target genes, such as urokinase-type plasminogen activator receptor (uPAR), intracellular adhesion molecule 1 (ICAM1), vascular cell adhesion molecule 1 (VCAM1), and matrix metalloproteinase 9 (MMP9), resulting in promoting BCa metastasis.

(Continued on next page)
Background
Bladder cancer (BCa) has the fourth highest incidence rate of all types of cancers worldwide and the eighth highest mortality rate [1], thus, representing a serious threat to public health. However, relapsed or metastatic BCa lacks treatment. Identifying new metastasis-related gene-therapy targets has become a clinical priority. Abnormal protein metabolism caused by ubiquitin dysregulation is closely related to tumorigenesis and progression [2]. The ubiquitin–proteasome system (UPS) is responsible for the degradation of most proteins [3]. Consequently, ubiquitin modification plays important roles in biological processes such as cell differentiation, apoptosis, DNA-damage repair, immune responses, and stress responses [4]. Protein ubiquitination involves a three-step cascade mediated by ubiquitin-activating (E1), ubiquitin-conjugating (E2), and ubiquitin-ligase (E3) enzymes, where E3 enzyme catalyzes ubiquitin transfer to substrate [5]. However, its exact molecular mechanism has not been fully elucidated. Therefore, elucidating the correlation between abnormal protein ubiquitination and BCa pathogenesis has important clinical significance for developing effective drugs and determining an accurate prognosis for patients with BCa.

The cullin/RING ubiquitin ligase (CRL) family, the largest UPS E3 family, facilitates the degradation of approximately 20% of protein substrates in cells [6]. CRL family is mainly composed of different cullin subunits, such as regulator of culls (ROC1) and ROC2, S-phase kinase-associated protein (SKP)1 adaptor protein, and F-box substrate-recognition subunits (SKP2 and beta-transducin repeats-containing protein [β-TrCP]) [7]. CRL family reportedly plays important roles in the occurrence and development of tumors; abnormal ubiquitination of tumor-suppressor protein p53 [8]; cell cycle-related proteins p21 and p27 [9, 10]; transcription factors c-Jun and c-Myc, and hypoxia-inducible factor 1α (HIF-1α) [11–13] can lead to tumorigenesis. The relative specificities of CRL E3 ligases in terms of substrate recognition, makes them potential targets for tumor therapy [14].

ROC1 (ring-box 1 or RBX1) forms the catalytic core of CRL complexes with different cullin subunits [15]. ROC1 is highly evolutionarily conserved and plays a key role in regulating CRL function. It is abnormally high-expressed in the liver, stomach, esophagus, breasts, lungs, and colon malignancies, and is associated with poor clinical prognosis [16–19]. Previously, we found that ROC1 was highly expressed in BCa and its knockdown inhibited BCa cell growth [20]. Further, ROC1 knockdown inhibited CRL activity and triggered p21 and p27 accumulation, leading to G2 phase arrest and cellular senescence [21]. We also found that ROC1 expression was significantly higher in muscular invasive BCa and positively correlated with epithelial–mesenchymal transition (EMT). ROC1 down-regulation caused DEP domain-containing mammalian target of rapamycin (mTOR)-interacting protein (DEP-TOR) accumulation, thereby inhibiting mTOR kinase activity. mTOR kinase inhibition can promote the mesenchymal–epithelial transformation and inhibit BCa cell metastasis [22]. These findings provide partial explanation for the important role of ROC1 in BCa progression. However, owing to the diversity of CRL complex-recognized substrates, the understanding of the role of ROC1 in BCa progression is still in its infancy. Notably, some CRLs recognize multiple substrates; β-TRCP [23] not only targets the degradation of β-catenin (which regulates the canonical Wnt-signaling pathway) [24], but also mediates the ubiquitination of phosphorylated inhibitor of kappa B alpha (p-IκBα). Therefore, β-TRCP may play a key role in regulating nuclear factor-kappa B (NF-κB) signaling [25]. Moreover, constitutive NF-κB activation promotes BCa invasion and metastasis, and high nuclear expression of the p65 is associated with poor prognosis [26]. Therefore, in the present study, we explored how ROC1 affects the NF-κB-signaling pathway to promote BCa invasion and metastasis through ubiquitination. The results of this study may provide new evidence for developing future targeted therapies against BCa.

Methods
Sample collection and patient follow-up
From January 2007 to October 2014, 46 paraffin-embedded BCa specimens and 10 paired tumor and adjacent normal tissue specimens were obtained from Shanghai General Hospital (Shanghai, China) for TMA construction and IHC analysis. Two pathologists examined and confirmed the tumor and adjacent normal tissues. None of the patients enrolled in the study received other treatments. Tumor staging and grade were evaluated according to the 1973 standards of the World Health Organization and the 2002 TNM system of the American Joint Committee on Cancer. All patients provided written informed consent before participating in the study. This study was approved by the Medical
TMA construction and IHC analysis
TMA construction and IHC were performed as described previously [27]. Briefly, the TMA was incubated with primary anti-ROC1 antibody (1:1000; Abcam, Cambridge, MA, USA) and anti-p65 antibody (1:800; Cell Signaling Technology, Danvers, MA, USA). ROC1-expression levels were analyzed semi-quantitatively using an immunoreactivity-scoring system as described previously [21]. Positive staining was quantified as the integral optical density (IOD)/unit area using ImageJ software (National Institutes of Health, Bethesda, MD, USA), and the mean densities were calculated.

Wound-healing and Transwell-invasion assays
Cells were grown in 35-mm culture dishes until they reached 90% confluency, then scratched with a sterile 200-μL pipette-tip. Photographs were taken at 0 and 24 h after scratching. Transwell-invasion assays were performed using 8-μm pore BioCoat Matrigel Invasion chambers (Corning NY, USA), according to the manufacturer's instructions. Cultured T24 and 5637 cells were trypsinized, resuspended in serum-free RPMI-1640, and added to the upper chambers at a density of 50,000 cells/well. RPMI-1640 with 10% FBS was added to the lower chambers. After a 24-h incubation, the cells were stained with 0.1% crystal violet for 30 min. Unmigrated cells were carefully removed from the upper chamber with a cotton swab and cells that passed through the membrane were counted in four random regions. Three independent experiments were performed.

Immunofluorescence staining
Cells in the dish were fixed with 4% paraformaldehyde and incubated with a primary antibody against p65 overnight at 4 °C. After washing several times with phosphate-buffered saline (PBS), the cells were incubated with an appropriate fluorophore-conjugated secondary antibody (Abcam) in the dark and counterstained with 4′,6-diamidino-2-phenylindole (DAPI; Beyotime, Shanghai, China). Images were captured using a confocal laser-scanning microscope (Leica TSC SP8, Wetzlar, Germany).

Protein extraction and WB analysis
Cellular proteins were extracted using RIPA lysis buffer (Thermo Fisher Scientific) and quantified using Pierce BCA Protein Detection Kit (Thermo Fisher Scientific).
Lysate proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to a 0.22-μm or 0.4-μm polyvinylidene fluoride membrane (Millipore, Billerica, MA), and incubated with antibodies against ROC1 (Abcam, ab133565), β-actin (Sangon, D191048), IKKα (Cell Signaling

![Image of ROC1 and p65 expression in normal bladder urothelium and bladder cancer tissues](image)

**Fig. 1** ROC1 expression correlated positively with nuclear p65 expression in BCa tissues and associated with a poor prognosis. **a** Immunostaining with antibodies against ROC1 and p65 (brown) was performed to detect ROC1 and p65 expression in normal bladder urothelial and BCa tissues. TMA sections were counterstained with hematoxylin. Scale bar, 100 μm. **b** Kaplan–Meier analysis for BCa patients with high ROC1 and nuclear p65 expression, and their association with poor overall survival. **c** Linear-regression analysis showed significant Pearson correlation between ROC1 expression and the mean nuclear p65 IOD/unit area in BCa TMA samples. **d** Representative images of ROC1 and p65 IHC staining in BCa metastasis and non-metastasis patients. **e** ROC1 expression in BCa cell lines and NUCs. **P** < 0.01 vs Non-metastatic Bca.
Technology, 11,930), IKKβ (Cell Signaling Technology, 8943), phospho-IKKα/β (Ser176/180, Cell Signaling Technology, 2697), phospho-IKKα/β (Ser176/180, Cell Signaling Technology, 2589), uPAR (Cell Signaling Technology, 12,863), ICAM1 (Cell Signaling Technology, 4915), VCAM1 (Cell Signaling Technology, 39,036), MMP9 (Cell Signaling Technology, 13,667), or ubiquitin (Cell Signaling Technology, 3936). GAPDH (Cell Signaling Technology, 5174), Histone H3 (Cell Signaling Technology, 4499), and β-actin served as loading controls. Binding of the primary antibody was detected by incubating the membranes with a horseradish peroxidase-conjugated secondary antibody, followed by visualization using an enhanced chemiluminescence (ECL) system (Bio-Rad, Hercules, CA, USA).

Cycloheximide and MG132 assays
CHX or MG132 was added to the culture medium at a final concentration of 30 μM or 20 mM, respectively. CHX group was pretreated with LPS for 2 h. Cell lysates were collected at 0, 2, 4, 8, and 12 h after CHX or MG132 treatment.

Ubiquitination assays
Pierce Classic Magnetic IP/Co-IP Kit (Thermo Fisher Scientific) was used for p-IκBα immunoprecipitation, according to the manufacturer’s instructions. Then, the supernatants were resolved by SDS-PAGE and subjected to WB analysis with anti-ubiquitin antibody.

Treatment with NF-κB inhibitor and siIκBα
ROC1-overexpressing cells were treated with BAY 11–7082 (5 μM) or DMSO for 12 h to evaluate their effects on p65 nuclear transport and cell invasion. siIκBα (Thermo Fisher Scientific) was used to transfect ROC1-overexpressing cells to knockdown IκBα, and scrambled siRNA was used as control. Cell invasion and p65 nuclear translocation were detected 48 h after transfection.

In vivo metastasis assay
Luciferase lentiviral vectors were purchased from GeneChem and transductions were performed according to the manufacturer’s instructions to generate T24 cells double-positive for EGFP and luciferase. After adding d-luciferin to the transduced cells (Yeason, Shanghai, China), the transfection efficiency was verified using a small-animal IVIS instrument (Lumina III, PerkinElmer, Boston, MA, USA). Double-positive T24 cells overexpressing ROC1 (LV-ROC1-OE cells) or transduced with empty vector control (LV-vector cells) were used for in vivo experiments. A single-cell suspension prepared in PBS (200 μL, containing 1 × 10⁶ cells) was injected into the tail veins of 6-week-old male nude mice (nu/nu; Shanghai SLAC Laboratory Animal Co., Ltd., Shanghai, China) (n = 10). After 8 weeks, in vivo imaging was performed, the mice were sacrificed, and number of lung-metastatic nodules was counted and subjected to IHC analysis for ROC1, uPAR, ICAM1, VCAM1, and MMP9 expression. All animal experiments were performed with the approval of the Animal Ethics Committee of Shanghai General Hospital. The animal experiments were performed in accordance with relevant guidelines and regulations of the Animal Care and Use Committees at the Shanghai General Hospital.

Statistical analyses
Results were analyzed using IBM SPSS Statistics software for Windows (version 22.0, SPSS, Inc., Chicago, IL, USA) and expressed as mean ± standard error of the mean of three independent experiments, performed in triplicate. Kaplan–Meier analysis and log-rank tests were used for survival analysis. Correlations between the expression levels of two proteins were analyzed using linear regression. Two-tailed Student’s t-test was performed to compare the

| Parameter                  | ROC1 expression |   |
|----------------------------|-----------------|---|
|                            | No. of cases    | Low | High | P-value |
| Age, years                 | 0.512           |     |      |         |
| < 65                       | 19              | 8   | 11   |         |
| ≥ 65                       | 37              | 19  | 18   |         |
| Gender                     | 0.566           |     |      |         |
| Male                       | 46              | 23  | 18   |         |
| Female                     | 10              | 4   | 6    |         |
| Tumor diameter (cm)        | 0.089           |     |      |         |
| < 5                        | 42              | 23  | 19   |         |
| ≥ 5                        | 14              | 4   | 10   |         |
| Histological grade         | 0.017           |     |      |         |
| Low                        | 24              | 16  | 8    |         |
| High                       | 32              | 11  | 21   |         |
| Tumor stage                | 0.063           |     |      |         |
| Ta-1                       | 22              | 14  | 8    |         |
| T2–4                       | 34              | 13  | 21   |         |
| LN metastasis              | 0.024           |     |      |         |
| N0                         | 41              | 24  | 17   |         |
| N1                         | 15              | 3   | 12   |         |
| Distant metastasis         | 0.020           |     |      |         |
| M0                         | 46              | 26  | 20   |         |
| M1                         | 10              | 1   | 9    |         |

Statistical significance (P < 0.05) is shown in bold
differences between groups. Multiple comparisons were performed with one-way analysis of variance (ANOVA), followed by Tukey’s post-hoc test. \( P < 0.05 \) was considered statistically significant.

**Results**

**ROC1 positively correlated with nuclear p65 expression in BCa tissues and associated with poor prognosis**

Here, we performed immunohistochemical (IHC) staining on a TMA, semi-quantitatively detected ROC1 and nuclear p65 expression, and analyzed the correlation between their expression levels (Fig. 1a). ROC1 expression showed a linear positive correlation with nuclear p65 expression (\( P < 0.001, R = 0.428 \); Fig. 1c). Survival analysis suggested that high expression of each protein was associated with poor prognosis (\( P < 0.05 \); Fig. 1b). High ROC1 expression was significantly associated with histological grade (\( P = 0.017 \)), lymph node metastasis (\( P < 0.024 \)), and distant metastasis (\( P = 0.020 \)) (Table 1). Furthermore, the expression level of nuclear p65 in patients with BCa metastasis was significantly higher than that in patients without metastasis (Fig. 1d).

**ROC1 expression affected BCa cell migration and invasion**

We evaluated ROC1 protein expression in normal urothelium cells (NUCs) and BCa cell lines (253J, J82, BIU87, T24, RT4, and 5637) (Fig. 1e) and selected T24 and 5637 cell lines, with highest ROC1 expression, for subsequent experiments. To determine whether ROC1 expression associated with BCa cell invasion and migration, ROC1-overexpression and -knockdown experiments were performed in vitro. Wound-healing (Fig. 2a) and Transwell-invasion assays (Fig. 2c) showed that small-interfering RNA (siRNAs)-mediated ROC1 knockdown significantly inhibited the invasion and migration of T24 and 5637 cells; ROC1 overexpression had the opposite effect (Fig. 2b, d).

**ROC1 promoted NF-κB-signaling activation and target-gene expression**

As many target genes of the NF-κB-signaling pathway are closely related to tumor invasion and migration, we...
Fig. 3 (See legend on next page.)
explored the effect of ROC1 on NF-κB signaling. First, we detected the expression of NF-κB-signal markers in T24 and 5637 cells after ROC1 knockdown and overexpression, by WB analysis. After ROC1 RNA interference, p-IκBα levels increased and p-p65 levels decreased, suggesting NF-κB signaling inhibition. ROC1 overexpression showed the opposite effect, suggesting NF-κB signaling activation, although no significant differences were observed in the expression levels of inhibitor of NF-κB kinase subunits (IKKa, IKKβ), p-IKKα/β, p65, or IκBα (Fig. 3a). Subsequently, we detected the expression levels of downstream NF-κB signaling-target genes related to tumor migration and invasion (urokinase-type plasminogen activator receptor [uPAR], intracellular adhesion molecule 1 [ICAM1], vascular cell adhesion molecule 1 [VCAM1], and matrix metalloproteinase 9 [MMP9]) by quantitative real-time polymerase chain reaction (qRT-PCR) and WB (Fig. 3b, c) analysis; their
expression levels was significantly higher in ROC1-OE group than that in control group, while, ROC1 knockdown showed the opposite effects.

**Activation of NF-κB signaling by ROC1 was p-IκBα dependent**

p-IκBα degradation and p65 nuclear translocation are key factors in NF-κB signal activation. To elucidate the mechanism whereby ROC1 activates NF-κB signaling, we treated BCa cells subjected to ROC1 knockdown or overexpression with NF-κB signaling agonist, lipopolysaccharide (LPS). The number of nuclear p65-positive cells significantly decreased in siROC1 group at 120 min post-LPS treatment, whereas more p65-positive cells were found in ROC1-OE group than control group at 90 min post-LPS treatment (Fig. 3d). We harvested cells after LPS stimulation for 0, 30, 60, or 120 min. Following nucleocytoplasmic separation, we observed a higher cytoplasmic p-IκBα expression in siROC1 group than in control group; ROC1-OE group showed an opposite trend. Additionally, no significant differences were observed in the cytoplasmic expression levels of p65 and IκBα between siROC1 and negative-control siRNA (siCONT) groups, or between empty-vector and ROC1-OE groups (Fig. 3e).
ROC1 promoted p-IκBα ubiquitination and degradation

To determine whether ROC1 can promote p-IκBα degradation through the UPS, we first treated ROC1-overexpressing and control cells with protein synthesis inhibitor, cycloheximide (CHX) and proteasome inhibitor, MG132. The p-IκBα half-life in CHX-treated ROC1-OE cells was significantly shorter than that in LPS-pretreated (2 h) control cells (Fig. 4a). In the unstimulated state, about 4 h after MG132 treatment, p-IκBα reached similar levels in both groups (Fig. 4c). To determine whether ROC1 can promote p-IκBα ubiquitination, we treated ROC1-overexpressing and control cells with MG132. After MG132 (10 μM) treatment for 6 h, cell lysates were immunoprecipitated with anti-p-IκBα antibody, followed by WB analysis of ubiquitin. Compared with control group, p-IκBα ubiquitination was higher in ROC1-OE group (Fig. 4b).

NF-κB inhibition and IκBα knockdown eliminated differences in BCa cell invasiveness induced by ROC1 overexpression

Next, we evaluated the effect of NF-κB inhibition in ROC1-overexpressing BCa (T24) cells. WB revealed that
BAY 11–7082 significantly reduced IκBα phosphorylation and inhibited nuclear p65 translocation. Corresponding invasion assays showed that BAY 11–7082 significantly inhibited T24 cell invasion in ROC1-OE and control groups (Fig. 5a, c). Moreover, compared to dimethyl sulfoxide (DMSO)-treated control cells, BAY 11–7082 eliminated the ROC1 overexpression-induced enhanced T24 cell invasiveness. Additionally, siRNA-mediated knockdown of IκBα expression, revealed opposite results in the invasion assays and by WB analysis (Fig. 5b).

**ROC1 overexpression promoted BCa metastasis in vivo**

To investigate the role of ROC1 in metastasis in vivo, we used a nude mouse model of lung metastasis to verify the effect of ROC1 overexpression. As T24 cells were more tumorigenic than 5637 cells, we selected them for the animal experiments. Enhanced green fluorescence protein (EGFP)- and luciferase-overexpressing T24 cells were transfected with either lentivirus-mediated ROC1 plasmids (LV-ROC1-OE cells) or empty vector control (LV-Vector cells). The cells were injected into the tail veins of nude mice, and lung metastases were observed using an in vivo imaging system. The bioluminescence signals of LV-ROC1-OE group were significantly higher than those of LV-Vector group (Fig. 6c). After 8 weeks, the mice were sacrificed and their lung tissues were analyzed. The pulmonary nodules in the stained lung sections of mice in both groups were observed (Fig. 6a). Compared with LV-Vector group (3.2 ± 1.92), LV-ROC1-OE group (14 ± 3.39; P < 0.001) had more lung metastatic nodules (Fig. 6b, d). The expression levels of uPAR, ICAM1, VCAM1, MMP9, and p65 in lung-nodule tissues, determined by IHC, were elevated in LV-ROC1-OE group (Fig. 6e). These results were consistent with the in vitro data, suggesting that ROC1 overexpression may promote tumor metastasis mediated by NF-κB-signaling activation.

**Discussion**

This study found that ROC1 played an important role in the malignant progression of BCa. First, we confirmed positive correlation between ROC1 and nuclear p65 expression, suggesting that ROC1 may be related to the constitutive activation of the NF-κB pathway. Moreover, aberrantly high ROC1 expression was associated with aggressive BCa tumor features and poor prognosis. ROC1 also promoted BCa cell migration and invasion. We found that ROC1 overexpression promoted the transcription of NF-κB-pathway target genes, uPAR, VCAM1, ICAM1, and MMP9, which enhanced BCa cell migration and invasion. The results of MG132 and CHX treatment indicated that the degradation of p-IκBα was mainly regulated by UPS, and ROC1 overexpression enhanced the turnover of p-IκBα. Furthermore, we discovered that ROC1 regulated the NF-κB-signaling pathway by controlling p-IκBα ubiquitination. Finally, we verified the role of ROC1 and NF-κB signaling in BCa progression in vivo.

Tumor metastasis is a complex process that involves the interactions of various proteins and multiple signaling pathways. In addition to regulating BCa cell EMT via DEPTOR–mTOR axis, ROC1 may also cooperate with NF-κB signaling in BCa metastasis. The nuclear p65 is believed to be constitutively expressed in human prostate [28], breast [29], liver [30], colon cancers [31] and mediates tumor metastasis. By analyzing 116 BCa patients’ tissues, Levidou et al. [26] found that BCa malignancy was closely related to nuclear p65 expression, suggesting that its constitutive expression is related to BCa progression. Similarly, we found that patients with higher p65 nuclear expression had a worse prognosis. Our research further confirmed the important role of NF-κB signaling in BCa progression.

NF-κB signaling is involved in numerous biological processes such as immune and inflammatory responses, proliferation, apoptosis, and EMT [32]. In the canonical NF-κB pathway, p65 is mostly present in the cytoplasm as an inactive complex that binds to IκBα. On receiving relevant signals, IKK phosphorylates IκBα, which is then ubiquitinated and subsequently degraded by the 26S proteasome. Finally, p65 rapidly enters the nucleus and activates gene transcription [33]. Therefore, regulation of the IκBα–p65 interaction is a key rate-limiting step in controlling NF-κB-signaling activity. NF-κB-signaling activation can promote tumor progression by chronically stimulating cancer cell proliferation, inhibiting cell death, and promoting the accumulation of mutations; it can up-regulate the expression of transcription factors, such as TWIST1 and SNAIL, to promote EMT [34] and induce the expression of uPAR, cell-adhesion molecules, and MMPs, which help cancer cells escape from the circulation [35]. NF-κB-signaling activation can also stimulate HIF-1α expression, thereby enhancing the hypoxic adaptation of tumor cells and the early survival of metastasis-initiating cells [36]. Our findings suggested that ROC1 overexpression accelerates ubiquitination-dependent degradation of p-IκBα in BCa cells, promotes nuclear translocation of p65, and activates expression of target genes involved in tumor metastasis. Furthermore, our observation that BAY 11–7082, a small-molecule NF-κB signaling inhibitor, effectively eliminated ROC1 overexpression-induced BCa cell invasion, suggests that NF-κB-signaling inhibition may be an effective treatment strategy for BCa with high ROC1 expression.

Notably, β-TrCP activates NF-κB signaling through ubiquitinated p-IκBα to promote tumor metastasis, as seen in oral squamous cell carcinoma [37]. Combined
with our current results, these data suggest that ROC1 may be an important component in β-TrCP complex. However, it is important to realize that ROC1 is a common component of many CRL E3 ligases and can combine with other CRL substrate-recognition subunits [38]. Consequently, one E3 ligase type could transfer ubiquitin to different substrates, and the same substrate could be recognized by several E3 ligases [39]. Therefore, the regulatory mechanism whereby ROC1 promotes BCa progression is complex. The interactions between ROC1 and other potential targets, and new modes of post-translational modifications to ROC1 itself should be further explored. There are some limitations of the present study. First, T24 and 5637 cells showed higher expression of ROC1 and were used for performing ROC1 knockdown experiments and further cellular experiments. We did not perform the ROC1 overexpression experiment using other cell line. Second, only T24 cells were carried out for NF-κB inhibition and IκBα knockdown studies, and 5637 cells should be involved. These limitations will be a part of our future research.

Conclusions
We found that ROC1 played an important role in BCa progression by controlling p-IκBα ubiquitination and regulating NF-κB signaling. The results may provide new insights regarding the relationship between ROC1 and NF-κB signaling that should help in understanding the tumorigenic mechanism of BCa and aid in developing targeted therapies.

Abbreviations
ROC1: Regulator of cullins 1; BCa: Bladder cancer; NF-κB: Nuclear factor-kappa B; p-IκBα: Phosphorylated inhibitor of kappa B alpha; uPAR: Urokinase-type plasminogen activator receptor; ICAM1: Intracellular adhesion molecule 1; VCAM1: Vascular cell adhesion molecule 1; MIM9: Matrix metalloproteinase 9; UPS: Ubiquitin proteasome system; CRL: Cullin/RING ubiquitin ligase; VCAM1: Vascular cell adhesion molecule 1; MMP9: Matrix metalloproteinase 9; Zhejiang Medical and Health Science and Technology Plan Project (No. 2020382934) and Traditional Chinese medicine of Zhejiang province science and technology plan project (2020ZB309).

Authors’ contributions
Conception and design of the research: Jianxin Qu and Wei Wang; acquisition of data: Qi Wu, Xiaoying Zhou, Peng Li and Mao Ding; analysis and interpretation of data: Qi Wu and Jun Wang; statistical analysis: Shengjie You, Zhaoyu Xu, Xuedong Chen and Mingyue Tan; drafting the manuscript: Qi Wu and Mao Ding; revision of manuscript for important intellectual content: Wei Wang and Jianxin Qu. All authors read and approved the final manuscript.

Funding
This study was funded by the grants from the Key Research and Development Project (No. 2017ZDYF11), Welfare Technology Applied Research Project (2019SJC462020GYX22), Zhejiang University Cooperation Project (No. 2018ZH212) of Lishui, Zhejiang Public Welfare Technology Application Research Project (No. LGF20H050003) and Zhejiang Medical and Health Science and Technology Plan Project (No. 2020382934) and Traditional Chinese medicine of Zhejiang province science and technology plan project (2020ZB309).

Availability of data and materials
Please contact author for data requests.

Declarations
Ethics approval and consent to participate
All the procedures carried out in the research involving human participants are in accordance with the ethical standards of the Research Ethics Committee of the Shanghai General Hospital of Shanghai Jiao Tong University. All subjects provided written informed consent. Animal research has been approved and carried out in strict accordance with the institutional ethical guidelines of the Committee on the Use of Live Animals of Shanghai General Hospital.

Consent for publication
Not applicable.

Competing interests
We have no competing interests.

Author details
1Department of Urology, The Sixth Affiliated Hospital of Wenzhou Medical University (The People’s Hospital of Lishui), Zhejiang 323000, China. 2Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan 430000, China. 3Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No.100 Haining Road, Hongkou District, Shanghai 200080, China. 4Department of Urology, The First people’s Hospital of Yancheng (Yancheng First Hospital, Affiliated Hospital of Nanjing University Medical School), No.66 South Renmin Road, Yancheng 224000, Jiangsu, China.

Received: 26 September 2020 Accepted: 3 April 2021

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13046-021-01935-5.

Acknowledgements
This work was supported by the Key Research and Development Project (No. 2017ZDYF11), Zhejiang University Cooperation Project (No. 2018ZH212) of Lishui, Zhejiang Public Welfare Technology Application Research Project (No. LGF20H050003) and Zhejiang Medical and Health Science and Technology Plan Project (No. 2020382934) and Traditional Chinese medicine of Zhejiang province science and technology plan project (2020ZB309).

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7–30. https://doi.org/10.3322/caac.21590.
2. Vucic D, Dikt VM, Wertz IE. Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol. 2011;12(7): 439–52. https://doi.org/10.1038/nrm3143.
3. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 2006;6(5):369–81. https://doi.org/10.1038/nrc1881.
4. Popovic D, Vucic D, Dikt I. Ubiquitination in disease pathogenesis and treatment. Nat Med. 2014;20(1):124–53. https://doi.org/10.1038/nm.3739.
5. Zheng N, Shabek N. Ubiquitin ligases: structure, function, and regulation. Annu Rev Biochem. 2017;86(1):129–57. https://doi.org/10.1146/annurev-biochem-060815-014922.
24. Su Y, Fu C, Ishikawa S, Stella A, Kojima M, Shitoh K, et al. APC is essential for targeting phosphorylated beta-catenin to the SCFbeta-Trcp ubiquitin ligase. Mol Cell. 2008;32(5):652–61. https://doi.org/10.1016/j.molcel.2008.10.023.

25. Yaron A, Hatzuabai A, Davis M, Lavon I, Armit S, Manning MA, et al. Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature. 1998;396(6701):590–4. https://doi.org/10.1038/25159.

26. Levidou G, Saetta AA, Korkolopoulou P, Papastasiou P, Gioti K, Pavlopoulos P, et al. Clinical significance of nuclear factor (NF-kappaB) levels in urothelial carcinoma of the urinary bladder. Virchows Arch. 2008;453(3):295–304. https://doi.org/10.1007/s00428-007-0560-y.

27. Wu Q, Zhou X, Li P, Wang W, Wang J, Tan M, et al. High NRBP1 expression promotes proliferation and correlates with poor prognosis in bladder cancer. J Cancer. 2019;10(18):4270–7. https://doi.org/10.7150/jca.32565.

28. Palayoor ST, Younell MF, Caldenwood SK, Coleman CN, Price BD. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene. 1999;18(5):389–94. https://doi.org/10.1038/sj.onc.1203160.

29. Yamaguchi N, Ito T, Azuma S, Ito E, Honma R, Yanagisawa Y, et al. Constitutive activation of nuclear factor-kappaB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines. Cancer Sci. 2009;100(9):1668–74. https://doi.org/10.1111/j.1349-7006.2009.01228.x.

30. Bae SI, Park J, Cho HJ, Jin Y, Lee S, Kim JH, et al. Targeting the p27 E3 ligase SCF (Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood. 2008;111(9):4690–9. https://doi.org/10.1182/blood-2007-09-112904.

31. Sakamoto K, Maeda S. Targeting NF-kappaB for colorectal cancer. Expert Opin Ther Targets. 2010;14(6):593–601. https://doi.org/10.1517/14728212003769903.

32. Zhang Q, Lenardo MJ, Baltimore D. 30 years of NF-kappaB. Science. 2008;320(5882):1701–5. https://doi.org/10.1038/science.112904.

33. Zeng Y, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, et al. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex: inhibition of a RING E3 ligase by the RING ubiquitin C-terminus. Nature. 2008;453(7195):769–73. https://doi.org/10.1038/nature06854.

34. Zhang Q, Lenardo MJ, Baltimore D. 30 years of NF-kappaB. Science. 2008;320(5879):769–73. https://doi.org/10.1126/science.112904.

35. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001;107(3):241–50. https://doi.org/10.1172/JCI11991.

36. Zhou W, Shi X, Peng Y, Wu M, Zhang X, Xie R, et al. HIF-1alpha promotes epithelial-mesenchymal transition and metastasis via direct regulation of ZEB1 in colorectal Cancer. PLoS One. 2015;10(1):e0129603. https://doi.org/10.1371/journal.pone.0129603.

37. Zhang B, Zhang Z, Li L, Qin YR, Hu H, Jiang C, et al. TSPAN15 interacts with BTRC to promote oesophageal squamous cell carcinoma metastasis via activating NF-kB signaling. Nat Commun. 2018;9(1):1423. https://doi.org/10.1038/s41467-018-03716-9.

38. Duda DM, Okszewski J, Tron AE, Hammel M, Lambert LJ, Waddell MB, et al. Structure of a glomulin-RBX1-CUL1 complex: inhibition of a RING E3 ligase through masking of its E2-binding surface. Mol Cell. 2012;47(3):371–82. https://doi.org/10.1016/j.molcel.2012.05.044.

39. Jackson PK, Eldridge AG. The SCF ubiquitin ligase: an extended look. Mol Cell. 2003;12(1):1–10. https://doi.org/10.1016/S1097-2765(03)00193-X.

40. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol. 2005;6(1):9–20. https://doi.org/10.1038/nrm1547.

41. Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, et al. Structure of the Cull-1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature. 2002;416(6882):703–9. https://doi.org/10.1038/416703a.

42. Tollerl LA, Jin A, Park, J, Zhang Y. Regulation of p53 by Mdm2 E3 ligase function is dispensable in embryogenesis and development, but essential in response to DNA damage. Cancer Cell. 2014;26(2):235–47. https://doi.org/10.1016/j.ccr.2014.06.006.

43. Yu HK, Gervais JA, Zhang H. Human CUL-1 associates with the SKP1/Skp2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc Natl Acad Sci U S A. 1998;95(19):11324–9. https://doi.org/10.1073/pnas.95.19.11324.

44. Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mensy D, et al. Targeting the p27 E3 ligase SCF (Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood. 2008;111(9):4690–9. https://doi.org/10.1182/blood-2007-09-112904.

45. Wertz IE, O'Rourke KM, Zhang Z, Dornan D, Arnott D, Deshaies RJ, et al. Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature. 1998;396(6701):590–4. https://doi.org/10.1038/25159.

46. Levidou G, Saetta AA, Korkolopoulou P, Papastasiou P, Gioti K, Pavlopoulos P, et al. Clinical significance of nuclear factor (NF-kappaB) levels in urothelial carcinoma of the urinary bladder. Virchows Arch. 2008;453(3):295–304. https://doi.org/10.1007/s00428-007-0560-y.

47. Wu Q, Zhou X, Li P, Wang W, Wang J, Tan M, et al. High NRBP1 expression promotes proliferation and correlates with poor prognosis in bladder cancer. J Cancer. 2019;10(18):4270–7. https://doi.org/10.7150/jca.32565.

48. Palayoor ST, Younell MF, Caldenwood SK, Coleman CN, Price BD. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene. 1999;18(5):389–94. https://doi.org/10.1038/sj.onc.1203160.